Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

소아 난치성 간질 중첩증에서 뇌척수액 백혈구 증가증의 임상적 의의

Clinical significance of cerebrospinal fluid pleocytosis in pediatric refractory status epilepticus

  • 김정미 (경북대학교 의과대학 소아과학교실) ;
  • 김영미 (경북대학교 의과대학 소아과학교실) ;
  • 권순학 (경북대학교 의과대학 소아과학교실)
  • Kim, Jung Mi (Departments of Pediatrics, College of Medicine, Kyungpook National University) ;
  • Kim, Young Mi (Departments of Pediatrics, College of Medicine, Kyungpook National University) ;
  • Kwon, Soon Hak (Departments of Pediatrics, College of Medicine, Kyungpook National University)
  • 투고 : 2006.07.21
  • 심사 : 2006.08.28
  • 발행 : 2006.10.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : RSE는 드물지 않으며 사망률이 높고 신경학적 후유증을 많이 남길 수 있는 중증 질환이다. 본 연구는 소아 난치성 간질 중첩증에서 뇌척수액 백혈구 증가증이 임상적으로 어떤 의미를 가지는지 알아보기 위해 시행하였다. 방 법 : 1999년 1월부터 2006년 1월까지 경북대학교 병원 소아과에 난치성 간질 중첩증을 주소로 입원한 37명의 환아 중에서 뇌척수액 검사를 시행한 25명의 환아를 대상으로 의무기록을 토대로 후향적 조사하였고 뇌척수액 백혈구 증가증이 있는 군과 없는 군을 나누어 비교하고, RSE가 간질의 첫 증상이었던 환아와 이전에 간질로 치료 받고 있던 환아 군을 나누어 비교하였다. 결 과 : 25명의 환아 중 6명에서 뇌척수액 백혈구 증가증이 있었고, 뇌척수액 백혈구 증가증이 없는 군에서 사망률과 필요약물 투여량에 유의한 차이가 없었다. 치료 후 경과는 뇌척수액 백혈구 증가증이 있는 군의 생존자가 더 심한 후유증이 남은 것으로 보이나 중추신경계 감염이 원인인 환아들을 제외하면 두군에서 치료 후 경과에 큰 차이가 없었다. 뇌척수액 백혈구 증가증이 있는 환아 들은 모두 처음 경련이 발생한 환아 들이었다. 결 론 : RSE로 진행한 경련 환아들 중에서 감염의 증거가 있을 경우는 뇌척수액 검사가 빠른 시간 안에 시행되어 중추신경계 감염 등의 원인 질환이 밝혀져야 하겠으나, 감염의 가능성이 적은 경우는 뇌척수액 검사 시기를 신중이 결정하는 것이 바람직하다고 생각된다. 그리고 경한 뇌척수액 백혈구 증가증은 예후에 특정한 영향을 주지 않으므로 감염이 의심되지 않는 경우에는 항생제, 항바이러스제 등의 사용에 신중을 기해야 한다고 생각한다.

Purpose : Refractory status epilepticus(RSE) is a serious neurological emergency in children. The mortality is high and the neurological outcome is not good. This study aimed to evaluate the clinical significance of cerebrospinal fluid(CSF) pleocytosis in refractory status epilepticus in children. Methods : From January 1999 to January 2006, 25 out of 37 children with refractory status epilepticus had spinal tapping. We retrospectively analyzed the data from these children's medical records. We compared the results between groups with and without CSF pleocytosis, and between a group with first seizure and a group with epilepsy. Result : Six out of 25 children had CSF pleocytosis. The group without CSF pleocytosis had a higher mortality rate and required higher doses of antiepileptic drugs as compared with the group with CSF pleocytosis. The group with CSF pleocytosis had much worse neurologic segualae. However, except for the children with CNS infection, the overall prognosis between the group with and without CSF pleocytosis was not significantly different. All children with CSF pleocytosis came in with first seizures. Conclusion : In children with RSE, a CSF study must be perfomed as soon as possible to exclude the possibility of CNS infection. A CSF study is even more important in cases of first seizure or CNS infection suspected. Mild CSF pleocytosis without evidence of infection does not seem to affect the prognosis, so physicians should therefore be more cautious in selecting antibacterial or antiviral agents for it.

키워드

참고문헌

  1. Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin North Am 2001;48:683-94 https://doi.org/10.1016/S0031-3955(05)70334-5
  2. Osorio I, Reed RC. Treatment of refractory generalized tonic-clonic status epilepticus with pentobarbital anesthesia after high-dose phenytoin. Epilepsia 1989;30:464-71 https://doi.org/10.1111/j.1528-1157.1989.tb05327.x
  3. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia 1996;37:863-7 https://doi.org/10.1111/j.1528-1157.1996.tb00039.x
  4. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus : frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205-10 https://doi.org/10.1001/archneur.59.2.205
  5. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005;76:534-9 https://doi.org/10.1136/jnnp.2004.041947
  6. Sahin M, Menache CC, Holmes GL, Riviello JJ, Jr. Prolonged treatment for acute symptomatic refractory status epilepticus : outcome in children. Neurology 2003;61:398-401 https://doi.org/10.1212/01.WNL.0000073139.53008.F2
  7. Bleck TP. Advances in the management of refractory status epilepticus. Crit Care Med 1993;21:955-7 https://doi.org/10.1097/00003246-199307000-00004
  8. Hamm SC, Kim CY . Clinical study of status epilepticus in children. J Korean Pediatr Soc 1990;33:790-5
  9. Kang YK, Kim SJ. The clinical characteristics of status epilepticus in children. J Korean Child Neurol Soc 1999;7: 71-8
  10. Lee KE, Kim WS. A Clinical study of acute symptomatic seizures in children. J Korean Pediatr Soc 2000;43:1254-62
  11. Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med 1980;69:657-66 https://doi.org/10.1016/0002-9343(80)90415-5
  12. Schmidley JW, Simon RP. Postictal pleocytosis. Ann Neurol 1981;9:81-4 https://doi.org/10.1002/ana.410090116
  13. Barry E, Hauser WA. Pleocytosis after status epilepticus. Arch Neurol 1994;51:190-3 https://doi.org/10.1001/archneur.1994.00540140100019
  14. Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993;34 Suppl 1:S37-53 https://doi.org/10.1111/j.1528-1157.1993.tb05905.x
  15. Simon RP. Physiologic consequences of status epilepticus. Epilepsia 1985;26 Suppl 1:S58-66 https://doi.org/10.1111/j.1528-1157.1985.tb05188.x
  16. Marik PE, Varon J. The management of status epilepticus. Chest 2004;126:582-91 https://doi.org/10.1378/chest.126.2.582
  17. Chen JW, Wasterlain CG. Status epilepticus : pathophysiology and management in adults. Lancet Neurol 2006; 5:246-56 https://doi.org/10.1016/S1474-4422(06)70374-X
  18. Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care 2006;4:35-46 https://doi.org/10.1385/NCC:4:1:035
  19. Kalviainen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus : a guide to treatment. CNS Drugs 2005;19:759-68 https://doi.org/10.2165/00023210-200519090-00003
  20. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam : a systematic review. Epilepsia 2002;43:146- 53 https://doi.org/10.1046/j.1528-1157.2002.28501.x
  21. van Gestel JP, Blusse van Oud-Alblas HJ, Malingre M, Ververs FF, Braun KP, van Nieuwenhuizen O. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005;65:591-2 https://doi.org/10.1212/01.wnl.0000173066.89001.f9
  22. Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bogousslavsky J. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004;45:757-63 https://doi.org/10.1111/j.0013-9580.2004.01904.x
  23. Kim SY, Kim JK, Lee JH. A Pediatric case of topiramate treatment for treatment for refractory status epilepticus. J Korean Epilepsy Soc 2004;8:171-4
  24. Oh HA, Kim CJ, Park KW, Woo YJ. The effect of intravenous continuous infusion midazolam against refractory status epilepticus in children. J Korean Child Neurol Soc 2000;8:80-6
  25. Sahin M, Menache CC, Holmes GL, Riviello JJ. Outcome of severe refractory status epilepticus in children. Epilepsia 2001;42:1461-7. https://doi.org/10.1046/j.1528-1157.2001.21301.x
  26. Lee SE, Kim HS, Yoo HJ. Study of priority between prognostic factors of status epilepticus in childhood. J Korean Child Neurol Soc 2005;13:15-22
  27. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus : effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62:1698-702 https://doi.org/10.1001/archneur.62.11.1698
  28. Wilder-Smith EP, Lim EC, Teoh HL, Sharm VK, Tan JJ, Chan BP, et al. The NORSE(new-onset refractory status epilepticus) syndrome : defining a disease entity. Ann Acad Med Singapore 2005;34:417-20